{"entity":{"id":"smc","kind":"institution","name":"Scottish Medicines Consortium","aka":["SMC"],"tldr":"Scotland's health technology assessment body, which advises NHS Scotland on new medicines and applies a more flexible approach for end-of-life and orphan cancer drugs.","summary":"Established in 2001, the Scottish Medicines Consortium advises NHS Scotland on the clinical and cost-effectiveness of all newly licensed medicines, working separately from NICE. Its Patient and Clinician Engagement process, introduced in 2014, gives additional weight to patient and clinician evidence for end-of-life and very rare conditions, and its ultra-orphan pathway allows access while evidence is collected, so some cancer drugs are available in Scotland before or without a NICE recommendation. The SMC is part of Healthcare Improvement Scotland and works with the MHRA and NICE on the Innovative Licensing and Access Pathway.","asOf":"2026-09-09","links":[{"label":"Scottish Medicines Consortium","url":"https://scottishmedicines.org.uk"}],"tags":[],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["nice","mhra","cruk"],"pathways":[],"terms":["real-world-evidence"],"trials":[],"people":["robert-peel"],"bottlenecks":["b-drug-pricing","b-rare-cancers"],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"city":"Glasgow","country":"GB","lat":55.864,"lng":-4.252,"institutionType":"government","website":"https://scottishmedicines.org.uk","programs":["Health technology assessment for NHS Scotland","Patient and Clinician Engagement (PACE) process","Ultra-orphan pathway","Innovative Licensing and Access Pathway partner"]},"route":"/institutions/smc/","neighbours":{"institution":[{"id":"cruk","kind":"institution","name":"Cancer Research UK","route":"/institutions/cruk/"},{"id":"ispor","kind":"institution","name":"ISPOR (The Professional Society for Health Economics and Outcomes Research)","route":"/institutions/ispor/"},{"id":"mhra","kind":"institution","name":"Medicines and Healthcare products Regulatory Agency","route":"/institutions/mhra/"},{"id":"nice","kind":"institution","name":"National Institute for Health and Care Excellence","route":"/institutions/nice/"}],"term":[{"id":"ilap","kind":"term","name":"ILAP (Innovative Licensing and Access Pathway)","route":"/terms/ilap/"},{"id":"nice-methods","kind":"term","name":"NICE technology appraisal methods (2022)","route":"/terms/nice-methods/"},{"id":"real-world-evidence","kind":"term","name":"Real-world evidence","route":"/terms/real-world-evidence/"}],"person":[{"id":"robert-peel","kind":"person","name":"Robert Peel","route":"/people/robert-peel/"}],"bottleneck":[{"id":"b-drug-pricing","kind":"bottleneck","name":"Prices and value","route":"/bottlenecks/b-drug-pricing/"},{"id":"b-rare-cancers","kind":"bottleneck","name":"Rare and paediatric cancers without markets","route":"/bottlenecks/b-rare-cancers/"}]}}